Clinical trials provided metabolic beneficial effects of anti-TNF-α agents (infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol) or IL-6 inhibitor (tocilizumab) on HbA1c, insulin resistance and insulin sensitivity in T2DM patients with psoriasis [152] or rheumatoid arthritis [153]. Here, IL6 is linked to type 2 diabetes mellitus.